Jianjie Zhu

Jianjie Zhu

Auto-generated profile, based on publicly available information

Jianjie Zhu

Department of Pulmonary and Critical Care Medicine The First Affiliated Hospital of Soochow University Suzhou China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2025 in Cancer Research
Verified
Journal Article
Closed access
JZJian Zhao
Jian Zhao
WZWeijie Zhang
Weijie Zhang
YZYuanyuan Zeng
Yuanyuan Zeng
DLDi Lu
Di Lu
CMChengkang Ma
Chengkang Ma
ZLZeyi Liu
Zeyi Liu
Despite progress in tumor-targeted therapy, oncogenic KRAS remains a major challenge in treating lung adenocarcinoma (LUAD). In clinical practice, KRASG12C inhibitors have limited response rates and are associated with acquired drug resistance. Cuproptosis is a recently identified form of copper (Cu)-mediated cell death, and previous studies have revealed that Cu metabolism plays an important role in the development of KRAS-driven tumors. Here, we revealed the therapeutic value of the Cu ionophore elesclomol (ES) for treating KRASG12-mutant-driven LUAD. KRASG12-mutant LUAD cells relied on the Cu exporter ATP7A to maintain Cu homeostasis. ES induced in cellular Cu accumulation and cuproptosis by upregulating expression of the E3 ligase OSTM1, which interacted with the IRGY motif of ATP7A to promote ubiquitination and degradation. KRASG12D transgenic mice and lung cancer organoids (LCOs) derived from the mice were used to validate the therapeutic effects of ES and Cu in vivo and in vitro. These findings indicate that KRASG12-driven LUAD relies on ATP7A-mediated Cu metabolic homeostasis, which can be perturbed with ES as an effective treatment strategy.

19 July 2022 in Cell Cycle
Verified
Journal Article
Closed access
ZLZeyi Liu
Zeyi Liu
JZJian Zhao
Jian Zhao
WZWeijie Zhang
Weijie Zhang
AWAnqi Wang
Anqi Wang
MJMin Jiao
Min Jiao
JHJian-an Huang
Jian-an Huang
Long non-coding RNAs (LncRNA) play important roles in multiple types of cancers. We addressed the role of LINC02535 by regulating the miR-30a-5p /GalNAc Transferase 3 (GALNT3) axis to promote the proliferation, migration, and invasion in lung adenocarcinoma (LUAD) cells. The Cancer Genome Atlas (TCGA) database screened differentially expressed lncRNAs. Quantitative real-time PCR analysis (qRT-PCR) confirmed that LINC02535 is highly expressed in LUAD tissues and cells. In vitro experiments showed that LINC02535 promotes the proliferation, migration, and invasion of LUAD cells. A xenograft mouse model was used to show that LINC02535 promotes tumor growth in vivo. RNA immunoprecipitation (RIP) and Dual-luciferase reporter assay results confirmed that LINC02535 targets miR-30a-5p. The Vicia villosa lectin (VVA) pull-down assay indicated that MUC1 is the glycosylation target of GALNT3, and western blot verified that NF-κB is the downstream signaling pathway of MUC1. We found that LINC02535 was increased in LUAD tissues and cells, and LINC02535 was correlated with the poor prognosis of LUAD patients. miR-30a-5p acts as a tumor suppressor in LUAD by targeting GALNT3. We also demonstrated that LINC02535 might function as the sponge of miR-30a-5p to up-regulate GALNT3, and consequently promote the proliferation and metastasis of LUAD. LINC02535 acts as a competing endogenous RNA (ceRNA) to interact with miR-30a-5p, thereby upregulating the expression of GALNT3, enhancing the function of MUC1, and activating the NF-κB signaling pathway, promoting the malignant progression of LUAD cells. Abbreviations: LncRNA:long non-coding RNA; LUAD: lung adenocarcinoma; TCGA: The Cancer Genome Atlas; GALNT3: GalNAc Transferase 3; qRT-PCR: quantitative real-time PCR analysis; RIP: RNA immunoprecipitation; SPF: specific pathogen-free; VVA: Vicia villosa lectin; ceRNA: competing endogenous RNA; MiRNAs: microRNAs; FBS: fetal bovine serum; PBS: Phosphate buffered saline; CCK-8: Cell Counting Kit-8; NSCLC: non-small cell lung cancer; OC: ovarian cancer; HCC: hepatocellular carcinoma.

20 July 2026 in Phytomedicine
Verified
Journal Article
Closed access
WWWenting Wu
Wenting Wu
YGYinhua Gong
Yinhua Gong
LZLiying Zhang
Liying Zhang
YSYuna Shao
Yuna Shao
WSWenxin Shao
Wenxin Shao
JZJianjie Zhu
Jianjie Zhu